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Abstract: BACKGROUND Infections after placement of cardiac implantable electronic devices (CIEDs)
are associated with substantial morbidity and mortality. There is limited evidence on prophylactic strate-
gies, other than the use of preoperative antibiotics, to prevent such infections. METHODS We conducted
a randomized, controlled clinical trial to assess the safety and efficacy of an absorbable, antibiotic-eluting
envelope in reducing the incidence of infection associated with CIED implantations. Patients who were
undergoing a CIED pocket revision, generator replacement, or system upgrade or an initial implantation
of a cardiac resynchronization therapy defibrillator were randomly assigned, in a 1:1 ratio, to receive the
envelope or not. Standard-of-care strategies to prevent infection were used in all patients. The primary
end point was infection resulting in system extraction or revision, long-term antibiotic therapy with in-
fection recurrence, or death, within 12 months after the CIED implantation procedure. The secondary
end point for safety was procedure-related or system-related complications within 12 months. RESULTS
A total of 6983 patients underwent randomization: 3495 to the envelope group and 3488 to the control
group. The primary end point occurred in 25 patients in the envelope group and 42 patients in the
control group (12-month Kaplan-Meier estimated event rate, 0.7% and 1.2%, respectively; hazard ratio,
0.60; 95% confidence interval [CI], 0.36 to 0.98; P = 0.04). The safety end point occurred in 201 pa-
tients in the envelope group and 236 patients in the control group (12-month Kaplan-Meier estimated
event rate, 6.0% and 6.9%, respectively; hazard ratio, 0.87; 95% CI, 0.72 to 1.06; P<0.001 for noninfe-
riority). The mean (±SD) duration of follow-up was 20.7±8.5 months. Major CIED-related infections
through the entire follow-up period occurred in 32 patients in the envelope group and 51 patients in the
control group (hazard ratio, 0.63; 95% CI, 0.40 to 0.98). CONCLUSIONS Adjunctive use of an antibac-
terial envelope resulted in a significantly lower incidence of major CIED infections than standard-of-care
infection-prevention strategies alone, without a higher incidence of complications. (Funded by Medtronic;
WRAP-IT ClinicalTrials.gov number, NCT02277990.).
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BACKGROUND
Infections after placement of cardiac implantable electronic devices (CIEDs) are associated 
with substantial morbidity and mortality. There is limited evidence on prophylactic strate-
gies, other than the use of preoperative antibiotics, to prevent such infections.
METHODS
We conducted a randomized, controlled clinical trial to assess the safety and efficacy of 
an absorbable, antibiotic-eluting envelope in reducing the incidence of infection associated 
with CIED implantations. Patients who were undergoing a CIED pocket revision, generator 
replacement, or system upgrade or an initial implantation of a cardiac resynchronization 
therapy defibrillator were randomly assigned, in a 1:1 ratio, to receive the envelope or not. 
Standard-of-care strategies to prevent infection were used in all patients. The primary end 
point was infection resulting in system extraction or revision, long-term antibiotic therapy 
with infection recurrence, or death, within 12 months after the CIED implantation proce-
dure. The secondary end point for safety was procedure-related or system-related complica-
tions within 12 months.
RESULTS
A total of 6983 patients underwent randomization: 3495 to the envelope group and 3488 
to the control group. The primary end point occurred in 25 patients in the envelope group 
and 42 patients in the control group (12-month Kaplan–Meier estimated event rate, 0.7% 
and 1.2%, respectively; hazard ratio, 0.60; 95% confidence interval [CI], 0.36 to 0.98; 
P = 0.04). The safety end point occurred in 201 patients in the envelope group and 236 
patients in the control group (12-month Kaplan–Meier estimated event rate, 6.0% and 
6.9%, respectively; hazard ratio, 0.87; 95% CI, 0.72 to 1.06; P<0.001 for noninferiority). The 
mean (±SD) duration of follow-up was 20.7±8.5 months. Major CIED-related infections 
through the entire follow-up period occurred in 32 patients in the envelope group and 51 
patients in the control group (hazard ratio, 0.63; 95% CI, 0.40 to 0.98).
CONCLUSIONS
Adjunctive use of an antibacterial envelope resulted in a significantly lower incidence of 
major CIED infections than standard-of-care infection-prevention strategies alone, without 
a higher incidence of complications. (Funded by Medtronic; WRAP-IT ClinicalTrials.gov 
number, NCT02277990.)
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It is estimated that 1.5 million patients receive cardiac implantable electronic devices (CIEDs) worldwide every year.1 Despite the 
use of various antibiotic prophylaxis regimens 
and advocacy of best surgical practices by society 
consensus statements,2,3 infections after place-
ment of CIEDs remain a major complication and 
are associated with substantial morbidity, mortal-
ity, and health care utilization.4-8 There is limited 
evidence on prophylactic strategies, other than 
the use of preoperative antibiotics, to reduce in-
fection. Although a number of studies support 
the use of local antibiotic delivery,9-14 a large, 
multicenter, randomized, controlled trial has 
been lacking. An absorbable, multifilament 
mesh envelope (TYRX Absorbable Antibacterial 
Envelope, Medtronic) is available to improve 
CIED stabilization in the subcutaneous pocket 
and to elute the antibiotics minocycline and 
rifampin. The aim of this randomized clinical 
trial was to eval uate the safety and effectiveness 
of the envelope in reducing CIED infection as ad-
junctive therapy to standard infection-prevention 
strategies.
Me thods
Trial Design
The Worldwide Randomized Antibiotic Envelope 
Infection Prevention Trial (WRAP-IT) was a multi-
center, randomized, controlled, prospective, single-
blind, postmarketing, interventional clinical trial. 
It compared the incidence of major CIED infec-
tions through 12 months after implantation 
among patients who received an absorbable anti-
bacterial envelope with the incidence among 
patients who did not receive the envelope.
Standard-of-care infection-prevention strategies 
(preprocedure intravenous antibiotics and sterile 
technique) were used in all patients. Patients were 
randomly assigned in a 1:1 ratio, with stratifica-
tion according to trial site and device type (pace-
maker or cardiac resynchronization therapy 
pacemaker [CRT-P] vs. implantable cardioverter–
defibrillator [ICD] or cardiac resynchronization 
therapy defibrillator [CRT-D]), to receive the en-
velope during their CIED procedure (envelope 
group) or not to receive the envelope (control 
group). (An image of the envelope is provided in 
Fig. S1 in the Supplementary Appendix, available 
with the full text of this article at NEJM.org.) 
Randomly assigned patients were followed at 
hospital discharge and at 6-month intervals until 
all the patients completed a minimum of 12 
months of follow-up. Patients were unaware of 
the trial-group assignments during the follow-
up period. Adverse events, including signs and 
symptoms of CIED infection, were assessed at 
each follow-up visit. The trial design has been 
described previously.15
Trial Oversight
The steering committee (Table S1 in the Supple-
mentary Appendix) designed and oversaw the 
conduct of the trial and data analyses in collabo-
ration with the sponsor, Medtronic. The proto-
col, approved by the ethics committee at each 
participating institution and associated national 
and local regulatory agencies, and statistical 
analysis plan are available at NEJM.org. All the 
patients provided written informed consent.
A clinical-events committee (Table S2 in the 
Supplementary Appendix), whose members were 
unaware of the randomization assignments, ad-
judicated all deaths and adverse events poten-
tially related to the implanted system or proce-
dure, including CIED infections. An independent 
data and safety monitoring committee (Table S3 
in the Supplementary Appendix), managed by the 
Cleveland Clinic Coordinating Center for Clini-
cal Research, met periodically during trial enroll-
ment and reviewed the formal interim analysis, 
which occurred when 5165 patients were en-
rolled and 3189 6-month postprocedure visits 
had been accrued, as prespecified by the statisti-
cal analysis plan. The first draft of the manu-
script was prepared by the steering committee, 
whose members had unrestricted access to the 
data, and was reviewed and edited by all the 
authors. All the authors vouch for the accuracy 
and completeness of the data and analyses re-
ported and for the fidelity of the trial to the 
protocol.
Trial Device
The TYRX envelope is an absorbable single-use 
envelope designed to hold a CIED when the de-
vice is implanted in the body. The envelope is 
constructed from a multifilament knitted mesh 
and coated with an absorbable polymer mixed 
with minocycline and rifampin, which elutes the 
antibiotics into the local tissue for a minimum 
A Quick Take is 
available at 
NEJM.org 
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of 7 days. The envelope is fully absorbed in ap-
proximately 9 weeks.
Patient Population
As described previously,15 our enrollment strat-
egy was to include patients who were perceived 
to be at increased risk for CIED infection on the 
basis of historical studies in the literature. This 
population included patients undergoing CIED 
generator replacement or a system upgrade with 
or without new leads, those undergoing CIED 
pocket or lead revision, and those undergoing an 
initial CRT-D procedure.13,16 Detailed inclusion and 
exclusion criteria are provided in Table S4 in the 
Supplementary Appendix. According to the proto-
col, pacemaker (including CRT-P) randomizations 
were capped at 25% of the target sam ple size.
End Points
The trial had one primary end point and three 
secondary end points. The primary end point 
was major CIED infection within 12 months 
(365 days) after the CIED procedure. CIED infec-
tion was defined as superficial cellulitis in the 
region of the CIED pocket with wound dehis-
cence, erosion, or purulent drainage; deep inci-
sional or space (pocket) surgical-site infection 
that met the Centers for Disease Control and 
Prevention criteria, independent of time from 
surgery; persistent bacteremia; or endocarditis. 
Major CIED infections were defined as infections 
that resulted in CIED system removal, an invasive 
CIED procedure (e.g., pocket revision without 
removal), treatment with long-term antibiotic 
therapy (if the patient was not a candidate for 
system removal) with infection recurrence after 
discontinuation of antibiotic therapy, or death. 
CIED infections that did not meet one or more 
of the criteria for major infection were classified 
as minor CIED infections. Secondary end points 
were CIED procedure-related or system-related 
complications within 12 months after the pro-
cedure, major or minor CIED infection within 12 
months, and major CIED infection regardless 
of when it occurred. Death from any cause was 
an ancillary end point of interest.
Statistical Analysis
The statistical methods and sample-size justifi-
cation have been described previously.15 Briefly, 
we calculated that a sample size of 6988 ran-
domly assigned patients would provide 90% 
power with the use of a Cox proportional-hazards 
model to evaluate the primary end point. Sample-
size calculation was performed with the use of 
simulation under the following assumptions: 
a rate of major CIED infection at 12 months after 
the procedure of 2% in the control group (2.4% 
among patients receiving an ICD or CRT-D and 
0.6% among those receiving a pacemaker or 
CRT-P), a 50% lower incidence of major CIED 
infection in the envelope group than in the con-
trol group, implantation of an ICD or a CRT-D in 
75% of the patients, an annualized attrition rate 
of up to 15%, and one interim analysis to assess 
success and futility with the use of group-sequen-
tial stopping boundaries to maintain an overall 
type I error rate of 5%.
The interim analysis occurred when 3189 ran-
domly assigned patients completed their 6-month 
visit and stopping boundaries were not met. The 
primary end point was evaluated with the use of 
a Cox proportional-hazards regression model 
stratified according to device type (pacemaker or 
CRT-P vs. ICD or CRT-D). Kaplan–Meier methods 
were used to construct event-rate plots. Time to 
event was set to the interval from the time of the 
procedure (or randomization) to the time of the 
first major CIED infection within 365 days. Data 
on patients who did not meet the primary end 
point were censored at their last follow-up visit 
or day 365, whichever occurred first. Homogene-
ity of the treatment effect was tested for sub-
groups by the inclusion of an interaction term 
for subgroup according to treatment.
Similar stratified Cox models were also used 
to compare the two trial groups with respect to 
the secondary end points and death, with the 
maximum follow-up time set to 365 days or the 
maximum observed days with respect to the end-
point definition. In addition, CIED procedure-
related or system-related complications were 
compared between the groups with the use of a 
noninferiority margin for the hazard ratio of 
1.33 (i.e., the hazard ratio for complications in 
the envelope group vs. the control group must be 
significantly lower than 1.33). All end points 
were evaluated on an intention-to-treat basis 
with the exception of the secondary end point of 
CIED complications, which was evaluated on an 
as-treated basis because a noninferiority hypoth-
esis was tested.17 The Holm multiple-testing pro-
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cedure was used to control the type I error for 
the three secondary objective analyses.
The sample-size calculation and all analyses 
were performed with the use of the R statistical 
package (R Project for Statistical Computing) or 
SAS software, version 9.4 (SAS Institute). P values 
of less than 0.0488 for the primary and secondary 
end points were considered to indicate statistical 
significance (with adjustment for the interim 
analysis). Independent statistical validation of the 
trial results was conducted by the Cleveland 
Clinic Coordinating Center for Clinical Research.
R esult s
Patients
Patient recruitment occurred from January 2015 
through July 2017, with 7075 patients enrolled 
and 776 implanting physicians at 181 centers in 
25 countries within North America, Europe, Asia, 
and South America (see the Supplementary Ap-
pendix); 92 patients did not undergo randomiza-
tion (Fig. 1). Among the remaining 6983 patients, 
3495 were assigned to the envelope group and 
3488 to the control group. Patient characteristics 
at baseline were balanced between the two groups 
except for a higher percentage of use of immu-
nosuppressive agents in the control group (Ta-
ble 1). The mean (±SD) age was 70.1±12.5 years; 
28.3% of the patients were women.
Procedure Characteristics
Procedure characteristics were balanced between 
the two groups. A total of 3429 patients who 
were assigned to the control group did not re-
ceive the envelope, and 3371 patients who were 
assigned to the envelope group received the en-
velope at the time of the CIED procedure. In the 
envelope group, the envelope was not success-
fully implanted in 10 procedures owing to limited 
pocket space; thus, the envelope was success-
fully implanted in 99.7% of procedure attempts 
(3371 of 3381 attempts) by 646 implanting phy-
sicians. The mean procedure time did not differ 
significantly between the two groups (56.3±46.2 
minutes in the envelope group and 55.0±48.0 
minutes in the control group; between-group 
difference, 1.3 minutes; 95% confidence interval 
[CI], −0.9 to 3.5).
Patient Follow-up
Patients were followed for a mean of 20.7±8.5 
months, with 89.4% of patients completing at 
least 12 months of follow-up (Fig. 1); the dura-
tion of follow-up did not differ significantly be-
tween the two groups. During the 12-month 
follow-up, 181 system revisions occurred in 153 
patients in the envelope group and 229 in 186 
patients in the control group (annualized rate, 
0.06 and 0.07, respectively; rate ratio, 0.79; 95% 
CI, 0.65 to 0.96).
Primary End Point
Within 12 months after the index CIED proce-
dure, there were 30 major infections in 25 patients 
in the envelope group and 45 major infections in 
Figure 1. Enrollment, Randomization, and Follow-up of the Trial Patients.
CIED denotes cardiac implantable electronic device.
6983 Underwent randomization
7075 Patients were enrolled
92 Were excluded
2 Died
31 Did not meet eligibility
criteria
50 Withdrew
1 Was withdrawn
by investigator
8 Had other reason
3495 Were assigned to receive envelope
44 Had no CIED procedure attempt
3451 Had CIED procedure attempt
2 Did not have device placed
3449 Had device placed
3371 Received envelope
78 Did not receive
envelope
3488 Were assigned to not receive 
envelope
31 Had no CIED procedure attempt
3457 Had CIED procedure attempt
3 Did not have device placed
3454 Had device placed
25 Received envelope
3429 Did not receive
envelope
3129 Were followed to 12 mo
153 Underwent system modification
55 Crossed over to not receive
envelope
366 Left the trial prematurely
170 Died
64 Withdrew
40 Were withdrawn
by investigator
66 Were lost to follow-up
26 Had other reason
3112 Were followed to 12 mo
186 Underwent system modification
20 Crossed over to receive
envelope
376 Left the trial prematurely
188 Died
53 Withdrew
34 Were withdrawn
by investigator
69 Were lost to follow-up
32 Had other reason
3495 Were included in the intention-
to-treat analysis
3488 Were included in the intention-
to-treat analysis
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Characteristic Envelope (N = 3495) Control (N = 3488)
Age
No. of patients evaluated 3490 3485
Mean — yr 70.0±12.6 70.1±12.4
Female sex — no. (%) 997 (28.6) 976 (28.0)
Body-mass index†
No. of patients evaluated 3477 3468
Mean 29.1±6.1 29.2±6.3
Medical history — no./total no. (%)
Cardiomyopathy 2364/3489 (67.8) 2374/3483 (68.2)
Coronary artery disease 1449/3489 (41.5) 1478/3483 (42.4)
Myocardial infarction 982/3489 (28.1) 934/3483 (26.8)
COPD 455/3489 (13.0) 418/3483 (12.0)
Diabetes 1080/3489 (31.0) 1085/3483 (31.2)
Renal dysfunction 585/3489 (16.8) 554/3483 (15.9)
Cardiovascular surgical history — no./total no. (%)
CABG 731/3489 (21.0) 760/3483 (21.8)
Valve surgery 323/3489 (9.3) 303/3483 (8.7)
No. of previous CIEDs
No. of patients evaluated 3487 3482
Mean 1.2±0.9 1.2±1.0
Time since first CIED
No. of patients evaluated 2810 2747
Mean — yr 9.0±4.9 9.1±5.1
Previous CIED infection — no./total no. (%)‡ 45/3489 (1.3) 53/3483 (1.5)
Baseline medications — no./total no. (%)
Antiplatelet 2007/3490 (57.5) 1972/3485 (56.6)
Anticoagulant 1377/3490 (39.5) 1390/3485 (39.9)
Antibiotic 36/3490 (1.0) 37/3485 (1.1)
Immunosuppressive 48/3490 (1.4) 85/3485 (2.4)
Insulin 348/3490 (10.0) 375/3485 (10.8)
Oral antidiabetic 615/3490 (17.6) 620/3485 (17.8)
Infection-management strategy — no./total no. (%)§
Periprocedure antibiotic 3402/3450 (98.6) 3413/3457 (98.7)
Preprocedure antibiotic 3250/3450 (94.2) 3291/3457 (95.2)
Antibiotic during procedure 690/3450 (20.0) 685/3457 (19.8)
Postprocedure antibiotic 987/3450 (28.6) 1058/3457 (30.6)
Pocket wash 2539/3450 (73.6) 2610/3457 (75.5)
CIED type planned at randomization — no. (%)
Low power
Pacemaker 723 (20.7) 709 (20.3)
CRT-P 133 (3.8) 157 (4.5)
High power
ICD 964 (27.6) 909 (26.1)
CRT-D 1675 (47.9) 1713 (49.1)
Procedure attempted but no CIED implanted — no. (%) 2 (0.1) 3 (0.1)
No procedure attempted — no. (%) 44 (1.3) 31 (0.9)
*  Plus–minus values are means ±SD. There were no significant differences between the two groups except for the use  
of immunosuppressive agents (P = 0.001), with values not adjusted for multiple testing; the standardized difference for 
immunosuppressive agents does not suggest imbalance, since the absolute value does not exceed 0.1. CABG denotes 
coronary-artery bypass grafting, CIED cardiac implantable electronic device, COPD chronic obstructive pulmonary dis-
ease, CRT-D cardiac resynchronization therapy defibrillator, and CRT-P cardiac resynchronization therapy pacemaker.
†  The body-mass index is the weight in kilograms divided by the square of the height in meters.
‡  Shown are patients with a CIED infection more than 12 months before trial enrollment.
§  Counts and percentages indicate patients with procedure attempts.
Table 1. Baseline Patient and Procedure Characteristics.*
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42 patients in the control group (12-month Kaplan–
Meier estimated event rate, 0.7% and 1.2%, re-
spectively; hazard ratio, 0.60; 95% CI, 0.36 to 
0.98; P = 0.04) (Fig. 2A and Table 2). With respect 
to the first major infection in each patient, 17 
were endocarditis or bacteremia and 50 were 
pocket infections. There were fewer pocket in-
fections but numerically more endocarditis or 
bacteremia infections in the envelope group than 
in the control group (Table 2, and Fig. S2 in the 
Supplementary Appendix). The most common 
major CIED criterion met in both groups was 
system removal (Table S6 in the Supplementary 
Appendix). Of the 36 organisms identified in the 
initial infection events, 23 were staphylococcus 
bacteria (Tables S7 and S8 in the Supplementary 
Appendix). Data on antibiotic susceptibility were 
not collected.
Secondary End Points and Death
We implemented the Holm procedure to control 
for multiple comparisons for the secondary end 
points. As shown in Table S9 in the Supplemen-
tary Appendix, the secondary end point that is 
listed first (complications through 12 months) 
passed the Holm criteria, but the subsequent 
two end points that are listed did not.
Complications that occurred within 12 months 
after the index CIED procedure and that were 
related to the CIED system or procedure oc-
curred in 201 patients in the envelope group 
and 236 patients in the control group (12-month 
Kaplan–Meier estimated event rate, 6.0% and 
6.9%, respectively; hazard ratio, 0.87; 95% CI, 
0.72 to 1.06; P<0.001 for noninferiority) (Fig. S3 
in the Supplementary Appendix). Excluding the 
primary end point of major infections, the Kaplan–
Meier 12-month complication event rates were 
5.7% in the envelope group and 5.9% in the 
control group.
Major or minor CIED infections within 12 
months occurred in 50 patients in the envelope 
group and 75 patients in the control group 
(12-month Kaplan–Meier estimated event rate, 
1.5% and 2.2%, respectively; hazard ratio, 0.67; 
95% CI, 0.47 to 0.96). Through the entire follow-
up period, major CIED infections occurred in 32 
patients in the envelope group and 51 patients in 
the control group (36-month Kaplan–Meier esti-
mated event rate, 1.3% and 1.9%, respectively; 
hazard ratio, 0.63; 95% CI, 0.40 to 0.98) (Fig. 2B).
A total of 349 deaths occurred in the envelope 
group and 365 deaths occurred in the control 
group throughout the follow-up period (36-month 
Kaplan–Meier rate of death, 17.4% and 17.8%, 
respectively; hazard ratio, 0.96; 95% CI, 0.83 to 
1.11) (Table S9 in the Supplementary Appendix).
Subgroup Analysis
A subgroup analysis was conducted to test for 
interaction among various baseline variables for 
the primary end point through 12 months. None 
of the differences between subgroups, inclusive of 
age, sex, or baseline characteristics, were signifi-
cant. In the subgroup receiving a high-power 
device (ICD or CRT-D), major CIED infections 
occurred in 18 patients in the envelope group 
and 35 patients in the control group (12-month 
Kaplan–Meier estimated event rate, 0.7% and 
1.4%, respectively; hazard ratio, 0.51; 95% CI, 
0.29 to 0.90). In the subgroup receiving a low-
power device (pacemaker or CRT-P), major CIED 
infections occurred in 7 patients in the envelope 
group and 7 patients in the control group 
(12-month Kaplan–Meier estimated event rate, 
0.9% and 0.8%, respectively; hazard ratio, 1.02; 
95% CI, 0.36 to 2.92). The interaction effect for 
subgroup according to device type was not sig-
nificant (Fig. 3).
In a post hoc analysis involving the patients 
who received an initial CRT-D, 536 were assigned 
to the envelope group and 586 to the control 
group. Major CIED infections occurred in 7 pa-
tients in the envelope group and 3 patients in 
the control group (12-month Kaplan–Meier esti-
mated event rate, 1.3% and 0.5%, respectively; 
hazard ratio, 2.55; 95% CI, 0.66 to 9.85).
Discussion
WRAP-IT was a randomized, controlled clinical 
trial to assess the safety and efficacy of the 
TYRX absorbable antibiotic-eluting envelope. In 
a population of patients who were at increased 
risk for CIED pocket infection, the envelope was 
significantly more effective at preventing infec-
tion than standard infection-control strategies 
alone. The efficacy objective was met, with 40% 
fewer patients in the envelope group than in the 
control group having a major infection through 
12 months of follow-up. The envelope was success-
fully implanted in 99.7% of procedure attempts, 
and the safety objective was met, because the 
envelope group did not have a higher incidence 
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of CIED procedure-related or system-related com-
plications than the control group.
CIED infection is a rare but serious event, and 
its management requires prolonged hospitaliza-
tion, which involves device and lead extraction 
with adjunctive antibiotic therapy.18 The risk of 
major complications with lead extraction is low, 
approximately 1 to 2%, but these can be fatal.19,20 
Figure 2. Kaplan–Meier Curves for First Major CIED Infection.
Results are for the overall randomized cohort through 12 months (Panel A) and through all follow-up (Panel B) and 
were not adjusted for multiple comparisons. Hazard ratios are derived from Cox regressions, with stratification ac-
cording to device class, and indicate the relative (envelope vs. control) risk of CIED infection. The insets show the 
same data on an enlarged y axis.
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Despite proper management of CIED infection, 
morbidity and both short- and long-term mor-
tality remain high.4-7 One randomized trial has 
shown a reduction in the risk of infection related 
to CIED procedures.21,22 In a trial of 1000 con-
secutive CIED procedures at a single center, intra-
venous administration of cefazolin before the 
procedure reduced the risk of infection by 81%.21 
More recently, an unblinded, cluster-randomized, 
crossover trial (Prevention of Arrhythmia Device 
Infection Trial [PADIT]) was conducted to assess 
the effect of incremental prophylaxis antibiotics 
before, during, and after the CIED procedure.22 
The use of the TYRX envelope was prohibited. 
The primary end point was not achieved because 
rates of hospitalization due to infection were not 
significantly reduced with incremental antibiot-
ics. In our trial, 98.7% of the patients received 
periprocedure antibiotics, 74.5% received pocket 
wash, and 29.6% received postprocedure antibi-
otics (Table 1).
These results add to the existing body of litera-
ture on the safety and efficacy of the envelope in 
reducing CIED infections.9-13 Although the use of 
the envelope may require dissection of a slightly 
larger CIED pocket, we did not observe a sig-
nificant difference in the rate of complications 
(e.g., hematoma) or procedure time that could 
be attributed to this. There were fewer system 
revisions in the envelope group than in the con-
trol group and no complications due to allergy 
to the envelope mesh, polymer, or antibiotics. 
Because the envelope is designed to prophylacti-
cally prevent deep incisional pocket infections, 
the trial excluded patients at high risk for sys-
temic infection due to other sources, as well as 
patients with existing infection. We observed 
61% fewer deep incisional pocket infections in 
the envelope group than in the control group 
(Table 2, and Fig. S2 in the Supplementary Ap-
pendix), and the effect was sustained through 
3 years of follow-up. The total number of all 
CIED infections (both major and minor) during 
12 months of follow-up was lower in the enve-
lope group than in the control group, although 
the envelope is not expected to prevent superfi-
cial infections, which tend to resolve without 
CIED removal. Why there were numerically more 
cases of endocarditis or bacteremia in the enve-
lope group is unclear.
Infections leading to an invasive procedure 
with or without CIED system removal, longer-
term suppressive antibiotic therapy, or death oc-
curred in 1.4% of standard-of-care patients re-
ceiving high-power devices (ICD or CRT-D) and 
0.8% of standard-of-care patients receiving low-
power devices (pacemaker or CRT-P); this find-
ing is in line with published trials.9,10,13 CIED 
infections occurred in 0.5% of standard-of-care 
patients receiving an initial CRT-D, which is lower 
than in published trials.13,23 The beneficial effects 
of the envelope in preventing major CIED infec-
tion in 12 months were more pronounced in 
patients with high-power devices than in those 
with low-power devices or an initial CRT-D. In 
general, patients with low-power devices and 
those who received an initial CRT-D were ob-
served to have low infection rates, which limits 
the assessment of infection reduction with the 
envelope. It is notable that of patients in the 
control group, four patients with low-power de-
vices and two patients with an initial CRT-D had 
a pocket infection within 12 months. Subgroup 
analyses of the primary end point according to 
age, sex, and baseline characteristics also showed 
no significant differences in effect, but these 
End Point
Envelope 
(N = 3495)
Control 
(N = 3488)
Total 
(N = 6983)
Hazard Ratio 
(95% CI)
number of patients (percent)
Primary end point: major CIED 
infection within 12 mo
25 (0.7) 42 (1.2) 67 (1.0) 0.60 (0.36–0.98)*
Type of major CIED infection
Pocket infection 14 (0.4) 36 (1.0) 50 (0.7) 0.39 (0.21–0.72)
Bacteremia or endocarditis 11 (0.3) 6 (0.2) 17 (0.2) 1.57 (0.61–4.05)
*  P = 0.04.
Table 2. Summary of Initial Major CIED Infections within 12 Months.
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results should be interpreted with caution owing 
to the low event rates.
Some limitations should be considered when 
interpreting the results of this trial. First, con-
secutive patients were not enrolled because this 
trial was limited to patients receiving generators 
from one device manufacturer (leads from other 
manufacturers were permitted). Second, the en-
velope was commercially available at the time of 
the trial, which may have influenced participa-
Figure 3. Subgroup Analysis of Major CIED Infections through 12 Months.
The P values are for the interaction between the randomization group and the subgroup variable. The body-mass 
 index is the weight in kilograms divided by the square of the height in meters. The CIED type is the type planned at 
randomization: low power (pacemaker or cardiac resynchronization therapy pacemaker) or high power (implantable 
cardioverter–defibrillator or cardiac resynchronization therapy defibrillator). COPD denotes chronic obstructive pul-
monary disease.
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tion in the trial. Third, the use of immunosup-
pressive agents was not balanced between the 
trial groups; however, among these patients, there 
was only one major infection within the first 12 
months, and therefore this is unlikely to influ-
ence interpretation of the results. Fourth, the lack 
of data on antibiotic susceptibility limits our 
ability to address the unknown risk of the devel-
opment of antibiotic resistance. Fifth, periproce-
dure and postprocedure infection-prevention strat-
egies including antibiotic use were not controlled; 
however, there is not yet clear evidence that a 
particular strategy influences the infection rate.
In conclusion, adjunctive use of an antibacte-
rial envelope resulted in a 40% lower incidence 
of major CIED infection than standard-of-care 
infection-prevention strategies alone. Patients 
who received the envelope did not have more 
procedure-related or system-related complica-
tions than those who did not receive it.
A data sharing statement provided by the authors is available 
with the full text of this article at NEJM.org.
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